You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Dosage and administration

Anoro Ellipta 55/22mcg (umeclidinium/vilanterol) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. 1

Below, you can find information on when to prescribe Anoro Ellipta and how it should be administered. You will also find other important information such as contraindications, warnings and precautions for use.


The recommended dose is one inhalation of Anoro 55/22mcg once daily. 1

Anoro Ellipta should be administered at the same time each day in order to maintain bronchodilation. 1

There is no dosage adjustment required in patients: 1

  • aged over 65 years
  • with renal impairment
  • with mild or moderate hepatic impairment

To provide your patients with more information, you can download the  Anoro Ellipta Patient Information Leaflet

Contraindications, warnings and precautions

Anoro Ellipta is contraindicated in patients with hypersensitivity to the active substances (umeclidinium and vilanterol) or the excipients (lactose monohydrate and magnesium stearate). 1
Anoro Ellipta should not be used in patients with asthma, and should be used with caution in patients: 1

  • with severe cardiovascular disease
  • with paradoxical bronchospasm
  • with urinary retention
  • with narrow-angle glaucoma
  • with convulsive disorders or thyrotoxicosis 
  • who are unusually responsive to β2-adrenergic agonists
  • with hereditary problems of galactose intolerance

How to take Anoro Ellipta

Anoro Ellipta contains 30 pre-dispensed doses and is ready to use. 1 Anoro Ellipta is administered in three simple steps. 1

Click here to find out more about the Ellipta device.

To provide your patients with clear information on how to correctly use Anoro Ellipta, you can download the Anoro Ellipta Patient Guide the Anoro Ellipta Patient Information Leaflet.

The Ellipta inhaler

The Ellipta inhaler has been designed with the patient in mind, and offers ease of use with reliable dose delivery 3 with significantly fewer patients making a critical error* while using the Ellipta inhaler vs. other commonly used inhalers.** 4

Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler 4

Significantly fewer patients made critical errors with Ellipta vs. other commonly used inhalers4

Adapted from van der Palen et al, 2016.

*Defined as errors that are likely to result in no, minimal or significantly reduced medication being inhaled.
**Anoro Ellipta vs. Diskus, MDI, Turbuhaler, HandiHaler and Breezhaler.

Storage and disposal

Anoro Ellipta should be stored in its original foil laminate tray to protect it from moisture and only removed before first use. Anoro Ellipta should not be stored above 30°C, and if refrigerated should be allowed to return to room temperature prior to inhalation. 1

The date of opening should be written on the inhaler in the space provided, and Anoro Ellipta should then be used within 6 weeks of first opening the tray. Disposal should be performed in accordance with local requirements. 1

Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health


  1. Anoro Ellipta SmPC.
  2. Anoro Ellipta Patient Information Leaflet (PIL).
  3. Riley JH et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873–1880.
  4. van der Palen et al. NPJ Prim Care Respir Med 2016; 26:1–8.

Trade marks are owned by or licensed to the GSK group of companies.

© 2018 GSK group of companies or its licensor.